Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GBA1 | P04062 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732674 | 0.93 | KMT2A (0.78) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4092299 | 0.91 | KMT2A (0.98) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4084986 | 0.87 | ABCB1 (0.78) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4754134 | 0.86 | KMT2A (0.70) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4753624 | 0.83 | KMT2A (0.72) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4754102 | 0.83 | KMT2A (0.72) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4095049 | 0.83 | MEN1 (0.72) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4084458 | 0.83 | KMT2A (0.72) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL1084135 | 0.82 | ABCB1 (1.00) | KMT2AMEN1ABCB1CYP1A2CYP3A4 | |
| SCHEMBL4095913 | 0.82 | ABCB1 (0.79) | KMT2AMEN1ABCB1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | KMT2A 1424/4885MEN1 718/4885ABCB1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.